Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effect of combined topotecan and veliparib
(ABT888) treatment in relapsed ovarian cancer with tumor progression and negative or unknown
BRCA mutation status.